Toggle navigation
Home
Search
Services
Blog
Contact
About
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H.
Pharming Technologies, B.V., Leiden, Netherlands
Search grants from Jan Nuijens
Search grants from Pharming Technologies, B.V.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
NC Rape Prevention and Education Program
Functional and Phenotypic Characterization of a New FSGS Gene
Human Behavorial Pharmacology of GHB
Residency Training in the General Practice of Dentistry
Recently added grants:
Macrophage differentiation and disease outcome in influenza infection
Signal transformations in the vestibulo-ocular circuit
Functional protein networks underlying T cell growth, proliferation and differentiation
Placental malaria: The role of inflammation at the maternal-fetal interface
Modulation of Host Cell Environment by Mycobacterial PE/PPE Proteins
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
3R01FD003086-01S1
Application #
7675911
Study Section
Special Emphasis Panel (ZFD1-OPD-L (C1))
Program Officer
Ganti, Usha
Project Start
2006-09-20
Project End
2009-08-31
Budget Start
2006-09-20
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
Indirect Cost
Institution
Name
Pharming Technologies, B.V.
Department
Type
DUNS #
City
Leiden
State
Country
Netherlands
Zip Code
Related projects
NIH 2008
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
NIH 2006
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
Comments
Be the first to comment on Jan Nuijens's grant